Skip to main content
An official website of the United States government

autologous CRISPR-Cas9 engineered regnase-1/SOCS1 dual-edited tumor infiltrating lymphocytes KSQ-004EX

A preparation of autologous tumor infiltrating lymphocytes (TILs) gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to inactivate both the endogenous genes suppressor of cytokine signaling 1 (SOCS1) and Regnase-1, with potential immunomodulating and antineoplastic activities. Upon infusion of the autologous CRISPR-Cas9 engineered Regnase-1/SOCS1 dual-edited TILs KSQ-004EX back into the patient, the cells specifically recognize, target and kill the patient's tumor cells. Inactivation of endogenous SOCS1 and Regnase-1 in the TILs increases responsiveness to cytokine signals, increases persistence and memory formation of TILs, and enhances anti-tumor responses.
Synonym:autologous CRISPR-Cas9 engineered TILs KSQ-004EX
autologous dual-edit eTILs KSQ-004EX
autologous engineered tumor infiltrating lymphocytes KSQ-004EX
autologous eTILs KSQ-004EX
autologous SOCS1/regnase-1 inactivated engineered TILs KSQ-004EX
autologous SOCS1/Regnase-1-edited TILs KSQ-004EX
CRISPR/Cas9-edited SOCS1/Regnase-1 gene-inactivated autologous TILs KSQ-004EX
Regnase-1/SOCS1 dual-edited human CRISPR/Cas9-engineered TILs KSQ-004EX
Code name:KSQ 004
KSQ 004EX
KSQ-004
KSQ-004EX
KSQ004
KSQ004EX
Search NCI's Drug Dictionary